Stay updated on Resmetirom Safety and Biomarkers Clinical Trial
Sign up to get notified when there's something new on the Resmetirom Safety and Biomarkers Clinical Trial page.

Latest updates to the Resmetirom Safety and Biomarkers Clinical Trial page
- ChecktodayNo Change Detected
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe MAESTRO-NAFLD-1 trial page now displays a 403 Forbidden error, replacing the full study record and its details with an access block. Users cannot view the trial's title, identifiers, conditions, locations, or dates.SummaryDifference18%

- Check35 days agoChange DetectedRevision label updated from v3.6.5 to v3.6.6, indicating a newer build of the page.SummaryDifference0.0%

- Check57 days agoChange DetectedThe page now shows a new revision label (v3.6.5) replacing the previous v3.6.4, indicating a deployment-level update to the page.SummaryDifference0.0%

- Check71 days agoChange DetectedUpdated the document revision tag from v3.6.3 to v3.6.4, signaling a newer revision of the page rather than a substantive content change.SummaryDifference0.0%

- Check78 days agoChange DetectedSteatotic Liver Disease was added to the list of related terms on the page, and Fatty Liver Disease was removed. This updates the page's terminology to reflect current disease nomenclature and enhances clarity for readers and indexing.SummaryDifference0.0%

- Check93 days agoChange DetectedThe page's revision tag was updated from v3.6.2 to v3.6.3, indicating a small update to the published version. It does not appear to modify visible content.SummaryDifference0.0%

Stay in the know with updates to Resmetirom Safety and Biomarkers Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Resmetirom Safety and Biomarkers Clinical Trial page.